EMERGENT BIOSOLUTIONS INC (EBS)
Sector: Health Care
2026 Annual Meeting Analysis
EMERGENT BIOSOLUTIONS INC · Meeting: April 29, 2026
Directors FOR
2
Directors AGAINST
2
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors
Against Analysis
Ms. Dayal has served since July 2022, meaning her tenure fully overlaps with the period during which EBS underperformed its compensation peer group by 24.3 percentage points over three years (EBS: -15.1% vs. peer median: +9.2%), which exceeds the 20-percentage-point trigger threshold for companies with negative absolute returns; the five-year check confirms this is sustained underperformance rather than a temporary dip, as EBS trailed peers by 82.6 percentage points over five years.
Dr. Harsanyi has served as a director since 2004 and as Board Chairman since 2022, meaning he bears significant accountability for the period during which EBS underperformed its compensation peer group by 24.3 percentage points over three years; the five-year check shows EBS trailed peers by 82.6 percentage points over five years, confirming this is sustained and not transient underperformance, so the vote is not downgraded to FOR.
For Analysis
Mr. Fowler was appointed to the board effective March 1, 2026, which is less than 24 months before the meeting date, so he is exempt from the TSR underperformance trigger under policy; he brings relevant healthcare and finance experience to support the company's turnaround.
Mr. Papa became CEO and director in February 2024, which is less than 24 months before the meeting date, so he is exempt from the TSR underperformance trigger under policy; as the incoming turnaround CEO he has not had sufficient time to be held accountable for prior-period stock underperformance.
Of the four Class II director nominees, two (Dayal, Harsanyi) receive AGAINST votes because their tenures substantially overlap with a period of severe and sustained stock underperformance — EBS trailed its compensation peer group by 24.3 percentage points over three years and 82.6 percentage points over five years, both well above the applicable policy thresholds. The other two nominees (John Fowler Jr. and Joseph Papa) are exempt from the TSR trigger because each joined the board within the past 24 months.
Say on Pay
✓ FORCEO
Joseph Papa
Total Comp
$5,321,147
Prior Support
84%%
CEO Joseph Papa received total compensation of approximately $5.3 million, which is within a reasonable range for a turnaround CEO at a ~$430 million market cap healthcare company, and the prior-year say-on-pay vote of 84% is above the 70% threshold that would require a mandatory re-evaluation response. The compensation structure is heavily variable (approximately 73% of target pay is performance-based on average across NEOs), which is consistent with good pay-for-performance design. However, the Compensation Committee's decision to pay out the 2023–2025 performance stock awards at 25% despite those awards not reaching the stated threshold performance level is a concern — this is discretion used to pay above what the plan's rules required — and shareholders should note this as a governance flag even though it does not independently trigger a No vote under policy.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$3,273,848
Non-Audit Fees
$37,502
The non-audit fees (tax services of $37,502) represent only about 1.1% of audit fees ($3,273,848), which is well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the proxy so the tenure trigger cannot fire, and there is no indication of material financial restatements attributable to audit failure; Ernst & Young is a Big 4 firm appropriate for a company of EBS's size.
Overall Assessment
The 2026 EBS annual meeting ballot presents four proposals; the most significant governance concern is the company's severe and sustained stock underperformance — down 15% over three years while its peer group returned +9%, and down 91% over five years — which triggers AGAINST votes for the two longest-tenured Class II director nominees (Dayal and Harsanyi) while the two newer nominees (John Fowler Jr. and Papa) are exempt. The auditor ratification passes cleanly on fees, and the Say on Pay earns a FOR vote given a reasonable pay structure and above-70% prior-year support, though shareholders should note the board's use of discretion to pay out performance stock awards that technically missed their stated goals.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing